- Home
- MED vs IKT Comparison
MED vs IKT Comparison
Compare MED & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- IKT
- Stock Information
- Founded
- MED 1980
- IKT 2008
- Country
- MED United States
- IKT United States
- Employees
- MED N/A
- IKT N/A
- Industry
- MED Packaged Foods
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- MED Consumer Staples
- IKT Health Care
- Exchange
- MED Nasdaq
- IKT Nasdaq
- Market Cap
- MED 156.7M
- IKT 167.2M
- IPO Year
- MED N/A
- IKT 2020
- Fundamental
- Price
- MED $13.68
- IKT $2.18
- Analyst Decision
- MED Hold
- IKT Buy
- Analyst Count
- MED 1
- IKT 2
- Target Price
- MED $16.50
- IKT $8.00
- AVG Volume (30 Days)
- MED 208.3K
- IKT 131.6K
- Earning Date
- MED 04-28-2025
- IKT 05-14-2025
- Dividend Yield
- MED N/A
- IKT N/A
- EPS Growth
- MED N/A
- IKT N/A
- EPS
- MED 0.19
- IKT N/A
- Revenue
- MED $602,463,000.00
- IKT N/A
- Revenue This Year
- MED N/A
- IKT N/A
- Revenue Next Year
- MED $2.10
- IKT N/A
- P/E Ratio
- MED $71.89
- IKT N/A
- Revenue Growth
- MED N/A
- IKT N/A
- 52 Week Low
- MED $12.87
- IKT $1.12
- 52 Week High
- MED $36.30
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- MED 43.76
- IKT 43.36
- Support Level
- MED $12.87
- IKT $2.08
- Resistance Level
- MED $14.07
- IKT $2.46
- Average True Range (ATR)
- MED 0.50
- IKT 0.17
- MACD
- MED -0.02
- IKT -0.01
- Stochastic Oscillator
- MED 44.02
- IKT 30.43
About MED MEDIFAST INC
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.